AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.63
+0.26 (+0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.37
Open26.39
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range26.37 - 26.91
52 Week Range24.56 - 42.00
Volume304,612
Avg. Volume401,955
Market Cap1.557B
Beta (3Y Monthly)-0.08
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.60
Trade prices are not sourced from all markets
  • Business Wire18 hours ago

    Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, and dupilumab is Regeneron and Sanofi’s fully human monoclonal antibody that inhibits signaling of IL-4 and IL-13 cytokines, which are believed to be major drivers of type 2 inflammation.

  • Business Wire20 days ago

    Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on Wednesday, October 3, 2018, at 10:55 a.m. Eastern Time. A live webcast of the fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies.

  • Business Wire2 months ago

    Aimmune Therapeutics to Present at Three Investor Conferences in September

    BRISBANE, Calif.-- -- Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will present at three investor conferences in ...

  • Associated Press2 months ago

    Aimmune Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had a loss of 91 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018.

  • Business Wire2 months ago

    Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the company’s President and CEO at the 2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15 at 1:55 p.m. Eastern Time. As Aimmune prepares to submit regulatory filings for marketing approval of AR101 in the United States and Europe, Dr. Dallas will provide a corporate overview and outline his vision for delivering on Aimmune’s commitment to serving those affected by food allergies. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

  • CNBC4 months ago

    With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance

    CNBC's Jim Cramer sits down with Stephen Dilly, the founding executive chairman and former CEO of Aimmune Therapeutics, to discuss the latest in food allergy treatment. Dilly addresses the challenges in treating peanut, milk and egg allergies and explains his company's novel approach. If you think food allergies are getting more and more prevalent in the United States, you're probably right.

  • TheStreet.com4 months ago

    Aimmune Therapeutics: An Interesting Business and Charts to Watch

    was mentioned on Jim Cramer's "Mad Money" last night during the Executive Decision section. AIMT is a biopharmaceutical company that is active in developing treatments for potentially life-threatening food allergies. In this daily bar of AIMT, below, we can see that prices made a minor topping pattern in December-February and a modest correction followed.

  • CNBC4 months ago

    Cramer Remix: The battle between these stocks proves why tech triumphs

    The "Mad Money" host also sits down with the CEOs of Williams-Sonoma and Aimmune Therapeutics. In the lightning round, Cramer can't condone selling a big-name pharmaceutical play. Digitization affects countless industries from retail to health care, but on Wednesday, CNBC's Jim Cramer flagged another under-the-radar group being affected: tax preparation companies.

  • ACCESSWIRE4 months ago

    Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

    Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.

  • Business Wire4 months ago

    Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas, M.D., as President and Chief Executive Officer. Dr. Dallas, a biotech and pharmaceutical industry executive with decades of global strategic and commercial experience, will join Aimmune as President and CEO on June 19th, and will also become a member of the Aimmune Board of Directors. Dr. Dallas succeeds Stephen Dilly, M.B.B.S., Ph.D., who announced his planned retirement late last year.

  • ACCESSWIRE5 months ago

    Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On May 30, 2018, the Company announced that it presented data from a new study on the psychosocial burden of peanut allergy in European countries at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. Active-Investors.com is currently working on the research report for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics.

  • Business Wire5 months ago

    Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that data from a new study on the psychosocial burden of peanut allergy in European countries were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. The APPEAL (Allergy to Peanuts Impacting Emotions and Life) study is a multi-dimensional, multi-phase effort, led by Aimmune Therapeutics in partnership with an expert panel of European food allergy patient advocacy group leaders and healthcare professionals (psychologist, dietician and allergists), to learn about the psychosocial burden of peanut allergy. In a quantitative online survey conducted in eight European countries, the APPEAL study examined the impact of peanut allergy on peanut-allergic children (as reported by a parent or caregiver), parents and caregivers of peanut-allergic children, and peanut-allergic adults.

  • Business Wire5 months ago

    Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that data on terminology used with oral immunotherapy were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. The data, from a recent online, Aimmune-supported survey of more than 100 practicing U.S. allergists and/or immunologists, showed considerable variability in the terminology used around oral immunotherapy. After reviewing a hypothetical patient’s progress through an oral food challenge, nearly 90 percent of the allergists surveyed selected terminology options that correctly assessed the patient’s results.

  • Business Wire5 months ago

    Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, reported additional results from its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy at the Congress of the European Academy of Allergy, Asthma, and Immunology (EAACI) 2018 in Munich. Aimmune previously announced that the trial met its primary and secondary efficacy endpoints in the pre-specified primary analysis of the 4-17 age cohort (see March 4 press release). Additional analyses including adults treated in the study were presented at EAACI.

  • Business Wire5 months ago

    Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy at the European Academy of Allergy and Clinical Immunology Congress 2018, taking place May 26–30 in Munich.

  • ACCESSWIRE5 months ago

    Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Stocks Insiders Just Bought This May
    Simply Wall St.5 months ago

    Stocks Insiders Just Bought This May

    While insiders may sell their shareholdings for many reasons, such as personal needs for cash, they tend to buy more shares with one motive in mind – increase their exposureRead More...

  • Business Wire5 months ago

    Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune execut

  • Associated Press5 months ago

    Aimmune Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had a loss of 92 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • Business Wire5 months ago

    Aimmune Therapeutics Announces First Quarter 2018 Financial Results

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018.

  • April Stocks Insiders Just Bought
    Simply Wall St.6 months ago

    April Stocks Insiders Just Bought

    It is commonly known that insider buying, management purchasing stock in the own firm, is an optimistic signal. Insiders have valuable insights into the company’s current operations and opportunities, soRead More...

  • Partnering with Nestle to tackle food allergies: Former A...
    CNBC Videos4 months ago

    Partnering with Nestle to tackle food allergies: Former A...

    Jim Cramer sits down with former Aimmune CEO Stephen Dilly to discuss how the company is fighting the country's most prevalent food allergies.